KANSAS CITY, Mo., and SAO PAULO, Brazil, July 28 /PRNewswire/ -- BBCI, a leading provider of innovative Phase II-IV clinical trials solutions and post-marketing studies, has announced a new partnership with VIGIUN, a Brazilian CRO, headquartered in Sao Paulo, Brazil which specializes in clinical and epidemiological research.
This partnership means that BBCI, which operates a European partnership with Advanced Medical Services (AMS) headquartered in Mannheim, Germany, has nearly 300 associates conducting clinical trials in North America, Eastern and Western Europe and Latin America. BBCI is the only CRO in the world focusing their expertise in late-stage drug development.
Sean Hart, BBCI's CEO, stated, "Over the past year, BBCI and VIGIUN have formed a strong bond with quality and top level service at its foundation. With this partnership and a continued focus on late-stage drug development, BBCI is able to offer our clients a growing international presence. This partnership will open up new streams of investigators, patients and markets in Latin America to complement our current offerings in North America and Europe, in order to assist the development of our clients' products."
Eduardo Forleo, VIGIUN's Medical Director stated, "Our purpose is to assist pharmaceutical companies to conduct their research programs, and thus to ensure greater quality and excellence in all projects within adequate timelines. With this new partnership between BBCI, AMS and VIGIUN, it is doubtless that we can achieve international success by the use of each partners' regional expertise."
Brazil and Latin America form the seventh largest pharmaceutical market in the world. Brazil is at the core of the pharmaceutical industry in Central and South America with 370 pharmaceutical companies, 26 of which are responsible for 85% of clinical trials. Large concentrations of possible patients in major cities, large numbers of potential investigators, many with clinical experience, and low production costs all create an environment ripe for development through this partnership.
BBCI is a high-quality, cost-effective Contract Research Organization dedicated to delivering on-time, reliable clinical trial management services to clients around the world. BBCI has been providing quality results in Phase II-IV studies for more than 28 years and has extensive post-marketing surveillance experience in every major therapeutic area, with more than 100,000 patients enrolled in studies during the past five years. More information about BBCI can be found at http://www.bbclinical.com/ , or by calling 1-800-366-8531.
VIGIUN is a quality Contract Research Organization located in Sao Paulo in southeast Brazil. VIGIUN provides therapeutic experience in epidemiological studies including respiratory disease and gastroenterology. They are well experienced in Large Phase IV studies, clinical research and data management. More information about VIGIUN can be found at http://www.vigiun.com.br/ or by calling (55 11) 3842-2277.